|Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …|
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro Jr, ...
The Lancet 393 (10183), 1819-1830, 2019
|Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance|
A Zippelius, P Batard, V Rubio-Godoy, G Bioley, D Liénard, F Lejeune, ...
Cancer research 64 (8), 2865-2873, 2004
|Four functionally distinct populations of human effector-memory CD8+ T lymphocytes|
P Romero, A Zippelius, I Kurth, MJ Pittet, C Touvrey, EM Iancu, P Corthesy, ...
The Journal of Immunology 178 (7), 4112-4119, 2007
|Selective survival of naturally occurring human CD4+ CD25+ Foxp3+ regulatory T cells cultured with rapamycin|
L Strauss, TL Whiteside, A Knights, C Bergmann, A Knuth, A Zippelius
The Journal of Immunology 178 (1), 320-329, 2007
|Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow.|
A Zippelius, P Kufer, G Honold, MW Köllermann, R Oberneder, ...
Journal of Clinical Oncology 15 (7), 2701-2708, 1997
|Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for …|
E Putz, K Witter, S Offner, P Stosiek, A Zippelius, J Johnson, R Zahn, ...
Cancer research 59 (1), 241-248, 1999
|Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions|
N Rufer, A Zippelius, P Batard, MJ Pittet, I Kurth, P Corthesy, JC Cerottini, ...
Blood 102 (5), 1779-1787, 2003
|Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.|
heinz laeubli, A Zippelius
|Antigenicity and immunogenicity of Melan‐A/MART‐1 derived peptides as targets for tumor reactive CTL in human melanoma|
P Romero, D Valmori, MJ Pittet, A Zippelius, D Rimoldi, F Lévy, V Dutoit, ...
Immunological reviews 188 (1), 81-96, 2002
|Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial|
M Pless, R Stupp, HB Ris, RA Stahel, W Weder, S Thierstein, MA Gerard, ...
The Lancet 386 (9998), 1049-1056, 2015
|Thymic selection generates a large T cell pool recognizing a self-peptide in humans|
A Zippelius, MJ Pittet, P Batard, N Rufer, M de Smedt, P Guillaume, ...
The Journal of experimental medicine 195 (4), 485-494, 2002
|A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade|
DS Thommen, VH Koelzer, P Herzig, A Roller, M Trefny, S Dimeloe, ...
Nature medicine 24 (7), 994-1004, 2018
|Ex vivo IFN-γ secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases|
MJ Pittet, A Zippelius, DE Speiser, M Assenmacher, P Guillaume, ...
The Journal of Immunology 166 (12), 7634-7640, 2001
|Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade|
P Müller, M Kreuzaler, T Khan, DS Thommen, K Martin, K Glatz, S Savic, ...
Science translational medicine 7 (315), 315ra188-315ra188, 2015
|Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors|
DS Thommen, J Schreiner, P Müller, P Herzig, A Roller, A Belousov, ...
Cancer immunology research 3 (12), 1344-1355, 2015
|Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines|
K Pantel, A Dickmanns, A Zippelius, C Klein, J Shi, W Hoechtlen-Vollmar, ...
JNCI: Journal of the National Cancer Institute 87 (15), 1162-1168, 1995
|Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international …|
RA Stahel, O Riesterer, A Xyrafas, I Opitz, M Beyeler, A Ochsenbein, ...
The lancet oncology 16 (16), 1651-1658, 2015
|Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12|
CS Garris, SP Arlauckas, RH Kohler, MP Trefny, S Garren, C Piot, ...
Immunity 49 (6), 1148-1161. e7, 2018
|The immune system and cancer evasion strategies: therapeutic concepts|
S Muenst, H Läubli, SD Soysal, A Zippelius, A Tzankov, S Hoeller
Journal of internal medicine 279 (6), 541-562, 2016
|Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study|
VH Koelzer, SI Rothschild, D Zihler, A Wicki, B Willi, N Willi, M Voegeli, ...
Journal for immunotherapy of cancer 4 (1), 1-8, 2016